Biocytogen Pharmaceuticals Secures Key Patent and Receives IND Approval for Anti-IGF-1R Antibody
Biocytogen Pharmaceuticals Beijing Co., Ltd., a prominent player in China’s healthcare sector, has recently achieved significant milestones in its biopharmaceutical endeavors. The company, listed on the Hong Kong Stock Exchange under the ticker 02315, has secured a Japan Patent Office (JPO) patent for its RenMab fully human antibody mouse platform. This development is a crucial step in expanding Biocytogen’s global patent portfolio for its RenMice fully human antibody/TCR platform, underscoring the company’s commitment to innovation and international recognition of its proprietary technologies.
The RenMab mice, a core component of Biocytogen’s RenMice platform, utilize the company’s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE) technology. This technology enables the replacement of murine immunoglobulin genes with human counterparts, allowing the mice to generate fully human antibodies with native-like diversity. This advancement significantly enhances the efficiency and success rate of antibody discovery, positioning Biocytogen as a leader in therapeutic antibody development.
In another significant development, Biocytogen, in collaboration with Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., announced that their co-developed anti-IGF-1R antibody, NTB003 (formerly BCG009), has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA). The approved indication for NTB003 is Thyroid Eye Disease (TED). This second-generation fully human monoclonal antibody was developed using Biocytogen’s RenMab platform, with Nanjing Chia Tai Tianqing handling the chemical, manufacturing, and control (CMC) process development, as well as toxicology studies and IND application.
NTB003 demonstrates enhanced molecular affinity, improved druggability, and an extended half-life compared to first-generation anti-IGF-1R therapeutics. In vitro studies have shown its potent signal-blocking activity and effective inhibition of hyaluronic acid release, indicating strong potential for further clinical development. These advancements highlight Biocytogen’s strategic focus on innovative drug development and its ability to collaborate effectively with industry partners.
As of June 3, 2025, Biocytogen’s close price on the Hong Kong Stock Exchange was HKD 17.04, with a market capitalization of HKD 5.44 billion. The company’s price-to-earnings ratio stands at 159.54, reflecting its growth potential and the market’s anticipation of future developments. These recent achievements are expected to bolster Biocytogen’s position in the biopharmaceutical industry and contribute to its ongoing success in the healthcare sector.